Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01077401 · ClinicalTrials.gov registry record · Phase 2
Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 152
- Enrollment target
NCT01077401: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT01077401 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 152 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01077401, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 152 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety, tolerability, bioactivity, and dose response of two different dosages (0.5 mg and 2.0 mg) of ranibizumab (RBZ) in patients with diabetic macular edema (DME).
Interventions
- DRUG Ranibizumab
- DRUG ranibizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2010-02 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01077401
The ClinicalTrials.gov registry entry for NCT01077401 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ranibizumab is the first listed.
NCT01077401 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01077401 about?
NCT01077401 is a clinical study titled "Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study". The purpose of this study is to investigate the safety, tolerability, bioactivity, and dose response of two different dosages (0.5 mg and 2.0 mg) of ranibizumab (RBZ) in patients with diabetic macular edema (DME).
What is the current status of trial NCT01077401?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 152 participants. The study started on 2010-02. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01077401?
The interventions under investigation include: Ranibizumab (DRUG), ranibizumab (DRUG).
Who is sponsoring clinical trial NCT01077401?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.